Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders in Canada. Its product candidates include Azetukalner, a selective Kv7 potassium channel opener in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

Xenon Pharmaceuticals Inc.

Xenon ( ($XENE) ) just unveiled an update. Xenon Pharmaceuticals will showcase six presentations at the European Epilepsy Congress 2026 in Athens, ...

Xenon to Spotlight Azetukalner Phase 3 and Mechanistic Data at EEC 2026

In a report released today, Tessa Romero from J.P. Morgan maintained a Buy rating on Xenon, with a price target of $82.00. Romero covers the Health...

J.P. Morgan Remains a Buy on Xenon (XENE)

Evercore ISI analyst Cory Kasimov maintained a Buy rating on Xenon today and set a price target of $80.00. Kasimov covers the Healthcare sector, fo...

Evercore ISI Reaffirms Their Buy Rating on Xenon (XENE)

An update from Xenon ( ($XENE) ) is now available. Xenon Pharmaceuticals reported its second-quarter 2026 results on August 6, highlighting strong ...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	XENE	$59.99	-3.13%	587.88K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	XENE	$59.99	-3.1%	587.88K
3
4
5
6

XENE

Get Xenon Pharmaceuticals Inc. Data in Excel

Get Xenon Pharmaceuticals Inc. Data in Excel